wife(72) has thyroiď.high Bipolar .She has developed pain in left arm between shoulder & elbow often very acute in night while lying oñ beď.No relief from physiotherapy done for 3 months light messaging from up to down relieves pain At one point muscle is stiff once in Mall the glass door while closing hit the point since then pain increased(muscle tear/ Neurolgia) Kindly advise which homeopathic is to be in both legs done in2006 but not able to moov without stick.
Thanks so much for those pearls of wisdom. You've probably saved me years of trial and error. I've ineffectively dipped in and out of weight training for 5 years now, with the typical accompanying splurges on a variety of supplements I don't understand and complicated programmes.
6 weeks ago I threw all supplements out except the multi-vitamin, cod liver oil and some protein shakes and now stick to one chest day, one back day and a leg day each week, with a mixture of rep ranges and as many compound exercises as possible. Keep It Simple Stupid certainly applies to beginners like me.
I'm glad to hear it'll be years before I hit a plateau, for now I'll stick to the basics.
In October 2017, the United States Food and Drug Administration (FDA) approved Shingrix, a non-live vaccine to prevent shingles. The Advisory Committee on Immunization Practices (ACIP) subsequently endorsed Shingrix as the preferred vaccine for the prevention of herpes zoster and its related complications in healthy adults 50 years of age and older. Shingrix is also recommended for adults who previously received the current shingles vaccine Zostavax , which was approved by the FDA in 2006. Shingrix, a two-dose vaccine, was found to prevent shingles in more than 90% of patients who received it in clinical trials . By preventing shingles, Shingrix also decreases the incidence of postherpetic neuralgia. Not only does Shingrix provide superior efficacy across all age groups, but it is also felt to confer longer lasting immunity than Zostavax, which has experienced temporary vaccine shortages due to supply issues. Shingrix is expected to be widely available to . consumers in early 2018. During clinical trials, the most common side effects associated with Shingrix included pain, swelling, and redness at the site of injection, headache , muscle aches, fever, chills, and upset stomach .